Pfizer (NYSE:PFE) Earns Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Pfizer (NYSE:PFE) in a research note released on Monday, Benzinga reports. The brokerage currently has a $45.00 price target on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently weighed in on PFE. Guggenheim assumed coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a buy rating and a $36.00 price objective on the stock. TD Cowen downgraded Pfizer from an outperform rating to a market perform rating and set a $32.00 price target on the stock. in a research note on Thursday, January 4th. Finally, Argus cut Pfizer from a buy rating to a hold rating in a research note on Friday, March 22nd. Twelve analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of Hold and an average target price of $36.88.

Pfizer Stock Down 0.1 %

Shares of NYSE:PFE opened at $25.39 on Monday. The firm has a market capitalization of $143.74 billion, a P/E ratio of 70.51, a P/E/G ratio of 1.16 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The stock has a 50 day moving average price of $27.14 and a 200-day moving average price of $28.74. Pfizer has a 52-week low of $25.23 and a 52-week high of $40.56.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.14 earnings per share. As a group, equities research analysts anticipate that Pfizer will post 2.24 EPS for the current fiscal year.

Hedge Funds Weigh In On Pfizer

A number of hedge funds have recently bought and sold shares of PFE. RB Capital Management LLC raised its holdings in shares of Pfizer by 6.7% during the first quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock valued at $282,000 after purchasing an additional 341 shares during the last quarter. Ironwood Wealth Management LLC. raised its stake in Pfizer by 1.1% during the 1st quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock valued at $1,868,000 after buying an additional 400 shares during the last quarter. United Bank lifted its holdings in shares of Pfizer by 0.6% during the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after buying an additional 290 shares during the period. Ergoteles LLC boosted its stake in shares of Pfizer by 136.3% in the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock worth $1,903,000 after buying an additional 21,209 shares during the last quarter. Finally, Mackenzie Financial Corp grew its holdings in shares of Pfizer by 6.4% in the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock worth $69,238,000 after acquiring an additional 79,887 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.